You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Claims for Patent: 12,514,822

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,514,822

Title:	Oral dosing of GLP-1 compounds
Abstract:	The present invention relates to improved uses of glucagon-like peptide 1 (GLP-1) peptides in oral therapy.
Inventor(s):	Flemming S. Nielsen, Per Sauerberg
Assignee:	Novo Nordisk AS
Application Number:	US19/192,233
Patent Claims:	1. A method for treating type 2 diabetes in a subject in need of such treatment, the method comprising: orally administering to the subject a composition comprising N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37) (semaglutide) and sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC); wherein the composition comprises 0.5-50 mg of the semaglutide; and wherein the composition is administered such that the ratio between the plasma half-life in days in humans of the semaglutide and the dosing interval in days of the composition is more than 2:1. 2. The method according to claim 1, wherein the composition comprises 100 mg of the SNAC. 3. The method according to claim 1, wherein the composition comprises 300 mg of the SNAC. 4. The method according to claim 1, wherein the composition is in the form of a tablet. 5. The method according to claim 1, wherein the semaglutide is the only GLP-1 peptide in the composition. 6. The method according to claim 5, wherein the composition comprises 100 mg of the SNAC. 7. The method according to claim 5, wherein the composition comprises 300 mg of the SNAC. 8. The method according to claim 6 or 7, wherein the composition is in the form of a tablet. 9. The method according to claim 1, wherein the subject suffers from obesity. 10. The composition according to claim 1, wherein the amount of SNAC is 50-90% (w/w) of the composition.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.